Non-Small Cell Lung Cancer NSCLC Clinical Trials

24 clinical trials for Non-Small Cell Lung Cancer NSCLC across international registries, including 11 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer — RECRUITING · PHASE1
• A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors — RECRUITING · PHASE1
• Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC — RECRUITING · PHASE1
• A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-8989 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutations — RECRUITING · PHASE1
• A Retrospective Observational Study of Nivolumab in Combination With Chemotherapy as Neoadjuvant Therapy for Resectable NSCLC Patients: Real-World Experience in Taiwan (NEOREAL) — RECRUITING
• Observational Multicenter Study in Patients Receiving Chemotherapy and Amivantamab for Metastatic Non-small Cell Lung Cancer — RECRUITING
• Phase II Study of Radiotherapy Followed by Durvalumab and Ceralasertib in Stage III NSCLC Patients With Thoracic Relapses +/- Oligometastases After PACIFIC Regimen — RECRUITING · PHASE2
• The Role of DNA and RNA in NGS Analyses for Advaced Stage NSCLC Patients — RECRUITING · NA
• Phase Ib/II Study of Vebreltinib With Furmonertinib in NSCLC Patients With c-Met Amplification After EGFR-TKI Failure — RECRUITING · PHASE1
• Efficacy Analysis of Neoadjuvant Treatment in Lung Cancer Using Low-dose Nivolumab Combined With Chemotherapy — RECRUITING · PHASE2
• a Single-arm, Single-center, Open Clinical Study — RECRUITING
• Safety, Tolerability, Immunogenicity, Pharmacodynamic Characteristics, and Preliminary Anti-tumor Activity of Personalized Cancer Vaccines Alone and in Combination With Toripalimab in Participants With Resected NSCLC — NOT_YET_RECRUITING · PHASE1
• Study of Durvalumab+Olaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With Lung Cancer (ORION) — ACTIVE_NOT_RECRUITING · PHASE2
• The Selective Personalized Radio-Immunotherapy for Locally Advanced NSCLC Trial — COMPLETED · PHASE2
• Limertinib Plus Carboplatin and Etoposide for EGFR-mutant NSCLC With SCLC Transformation After EGFR-TKI Progression — NOT_YET_RECRUITING · PHASE2
• Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON). — ACTIVE_NOT_RECRUITING · PHASE3
• A Prospective Multicenter Study of the Association Between TCM Syndromes and EGFR-TKI Efficacy in Lung Cancer Patients — NOT_YET_RECRUITING
• A multicenter, open-label, non-comparative, single-arm, phase II trial of datopotamab deruxtecan for non-squamous non-small cell lung cancer patients with active brain metastases (The TUXEDO-5 Study) — OTHER · PHASE2
• A Global Study to Assess the Effects of MEDI4736 (Durvalumab), Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer — COMPLETED · PHASE3
• Clinical Study of Trop2 CAR-NK in the Treatment of Relapsed/Refractory Non-Small Cell Lung Cancer (NSCLC) — NOT_YET_RECRUITING · PHASE1
• Clinical Study of 18F-Alfatide Injection PET/CT — NOT_YET_RECRUITING · PHASE3
• A Clinical Trial of Durvalumab (MEDI4736) as 1st Line Therapy in Advanced Non-small Cell Lung Cancer Patients — COMPLETED · PHASE2
• Observational Study of Durvalumab in Patients With Non-small-cell Lung Cancer in the United Kingdom — COMPLETED
• Treatment Patterns, Clinical Outcomes, and Healthcare Resource Utilization Associated With Chinese Patients With Advanced Lung Cancer — COMPLETED

Refine this search